2023
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment
de Oliveira M, de Barros P, de Mathis M, Boavista R, Chacon P, Echevarria M, Ferrão Y, de Queiroz Vattimo E, Lopes A, Torres A, Diniz J, Fontenelle L, do Rosário M, Shavitt R, Miguel E, da Silva R, da Conceição Costa D. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment. Brazilian Journal Of Psychiatry 2023, 45: 146-161. PMID: 36749887, PMCID: PMC10154009, DOI: 10.47626/1516-4446-2022-2891.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsAdult obsessive-compulsive disorderObsessive-compulsive disorderPharmacological treatmentReuptake inhibitorsEvidence-based pharmacological interventionsFirst-line pharmacological treatmentAmerican Psychiatric Association guidelinesEvidence-based pharmacological treatmentFirst-line treatmentNorepinephrine reuptake inhibitorsPrimary outcome measureSerotonin reuptake inhibitorsGlutamate-modulating agentsHigh-quality evidenceAmerican Heart AssociationLevel of evidenceTreatment of OCDBrazilian Research ConsortiumAdult patientsHeart AssociationTolerable dosesAssociation guidelinesTreatment recommendationsPharmacological interventions
2022
Right Prefrontal Cortical Thickness Is Associated With Response to Cognitive-Behavioral Therapy in Children With Obsessive-Compulsive Disorder
Bertolín S, Alonso P, Martínez-Zalacaín I, Menchón J, Jimenez-Murcia S, Baker J, Bargalló N, Batistuzzo M, Boedhoe P, Brennan B, Feusner J, Fitzgerald K, Fontaine M, Hansen B, Hirano Y, Hoexter M, Huyser C, Jahanshad N, Jaspers-Fayer F, Kuno M, Kvale G, Lazaro L, Machado-Sousa M, Marsh R, Morgado P, Nakagawa A, Norman L, Nurmi E, O’Neill J, Ortiz A, Perriello C, Piacentini J, Picó-Pérez M, Shavitt R, Shimizu E, Simpson H, Stewart S, Thomopoulos S, Thorsen A, Walitza S, Wolters L, Group E, Real E, Segalas C, Morer A, Brem S, Ferreira S, Moreira P, Hagen K, Hamatani S, Takahashi J, Yoshida T, de Mathis M, Miguel E, Pariente J, Tang J, Thompson P, van den Heuvel O, Stein D, Soriano-Mas C. Right Prefrontal Cortical Thickness Is Associated With Response to Cognitive-Behavioral Therapy in Children With Obsessive-Compulsive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2022, 62: 403-414. PMID: 36526161, PMCID: PMC10065927, DOI: 10.1016/j.jaac.2022.07.865.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyObsessive-compulsive disorderCBT responseCortical thicknessMagnetic Resonance Imaging PredictorsBaseline cortical thicknessPrefrontal cortex thicknessFirst-line treatmentRostral middle frontal gyrusPrefrontal cortical thicknessIdentification of predictorsHigher cortical thicknessMiddle frontal gyrusRight prefrontal cortexCortical surface areaMechanism of actionAdult patientsImaging predictorsPrefrontal cortex regionsClinical managementLarge seriesSubcortical volumesAdult populationFrontal polePrefrontal cortexWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD
Bandelow B, Allgulander C, Baldwin D, da Conceição Costa D, Denys D, Dilbaz N, Domschke K, Hollander E, Kasper S, Möller H, Eriksson E, Fineberg N, Hättenschwiler J, Kaiya H, Karavaeva T, Katzman M, Kim Y, Inoue T, Lim L, Masdrakis V, Menchón J, Miguel E, Nardi A, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein D, Tsai S, Van Ameringen M, Vasileva A, Wang Z, Zohar J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD. The World Journal Of Biological Psychiatry 2022, 24: 118-134. PMID: 35900217, DOI: 10.1080/15622975.2022.2086296.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsRepetitive transcranial magnetic stimulationCognitive behavioral therapyFirst-line treatmentDeep brain stimulationSSRI treatmentBiological Psychiatry (WFSBP) GuidelinesSecond-line medicationsNon-pharmacological treatmentSerotonin reuptake inhibitorsNon-pharmacological interventionsTreatment-resistant casesTranscranial magnetic stimulationWorld FederationTreatment of anxietyPosttraumatic stress disorderTreatment of OCDReuptake inhibitorsMedication treatmentPharmacological treatmentSNRI venlafaxineInternet-CBTConsensus panelMagnetic stimulationBrain stimulationKetamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Bandeira ID, Lins-Silva DH, Cavenaghi VB, Dorea-Bandeira I, Faria-Guimarães D, Barouh JL, Jesus-Nunes AP, Beanes G, Souza LS, Leal GC, Sanacora G, Miguel EC, Sampaio AS, Quarantini LC. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard Review Of Psychiatry 2022, 30: 135-145. PMID: 35267254, DOI: 10.1097/hrp.0000000000000330.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSystematic reviewN-methyl-D-aspartate receptor antagonistAppropriate washout periodOpen-label trialPlacebo-controlled trialFirst-line treatmentRetrospective chart reviewUse of ketamineEffects of ketamineMeta-analysis protocolCombination of ketaminePubMed/MEDLINEPreferred Reporting ItemsMore effective treatmentsPotent N-methyl-d-aspartate receptor antagonistKetamine treatmentChart reviewGlutamate modulatorsGood tolerabilityReuptake inhibitorsWashout periodCase reportGlutamatergic neurotransmissionReceptor antagonist
2011
Gray Matter Volumes in Obsessive-Compulsive Disorder Before and After Fluoxetine or Cognitive-Behavior Therapy: A Randomized Clinical Trial
Hoexter M, de Souza Duran F, D'Alcante C, Dougherty D, Shavitt R, Lopes A, Diniz J, Deckersbach T, Batistuzzo M, Bressan R, Miguel E, Busatto G. Gray Matter Volumes in Obsessive-Compulsive Disorder Before and After Fluoxetine or Cognitive-Behavior Therapy: A Randomized Clinical Trial. Neuropsychopharmacology 2011, 37: 734-745. PMID: 22030709, PMCID: PMC3260985, DOI: 10.1038/npp.2011.250.Peer-Reviewed Original ResearchConceptsCognitive behavior therapyObsessive-compulsive disorderGray matter volumeLeft putamenClinical trialsOCD patientsGM volumeMatter volumeSignificant GM volume changesPathophysiology of OCDFluoxetine-treated patientsGM volume abnormalitiesMatched-healthy controlsTreatment-naive patientsFirst-line treatmentStructural brain abnormalitiesGM volume changesCBT-treated patientsGroup cognitive behavior therapySmaller GM volumeRegional brain volumesRegional brain morphologyAnterior cingulate cortexStructural magnetic resonanceRegional gray matter volumeRisk factors for early treatment discontinuation in patients with obsessive-compulsive disorder
Diniz J, Malavazzi D, Fossaluza V, Belotto-Silva C, Borcato S, Pimentel I, Miguel E, Shavitt R. Risk factors for early treatment discontinuation in patients with obsessive-compulsive disorder. Clinics 2011, 66: 387-393. PMID: 21552660, PMCID: PMC3071996, DOI: 10.1590/s1807-59322011000300004.Peer-Reviewed Original ResearchConceptsEarly treatment discontinuationSelective serotonin reuptake inhibitorsTreatment discontinuationObsessive-compulsive disorder patientsObsessive-compulsive disorderDisorder patientsFirst-line treatmentGroup of patientsSerotonin reuptake inhibitorsStructured Clinical InterviewLogistic regression analysisLogistic regression modelsGeneralized anxiety disorderCognitive behavioral therapyMann-Whitney testClinical characteristicsCompliant patientsDiscontinuation ratesReuptake inhibitorsPsychiatric comorbidityClinical correlatesTreatment modalitiesRisk factorsSomatization disorderDiscontinuation
2009
The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder
Shavitt R, Valério C, Fossaluza V, da Silva E, Cordeiro Q, Diniz J, Belotto-Silva C, Cordioli A, Mari J, Miguel E. The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder. European Archives Of Psychiatry And Clinical Neuroscience 2009, 260: 91-99. PMID: 20077119, DOI: 10.1007/s00406-009-0015-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetAnxietyDepressionDiagnostic and Statistical Manual of Mental DisordersFemaleFollow-Up StudiesHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsStatistics, NonparametricStress Disorders, Post-TraumaticTreatment OutcomeConceptsHistory of traumaPost-traumatic stress disorderObsessive-compulsive disorderTreatment responseHT groupBeck Depression InventoryPTSD groupBeck Anxiety InventorySpecific OCD symptom dimensionsConventional treatmentOCD symptom dimensionsOCD patientsSelective serotonin reuptake inhibitorsStress disorderFull DSM-IV criteriaFirst-line treatmentSerotonin reuptake inhibitorsCase series studyPoor treatment responseResistant OCD patientsSymptom dimensionsGreater treatment responseDSM-IV criteriaGreater reductionGroup cognitive behavioral therapy
2008
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
Bandelow B, Zohar J, Hollander E, Kasper S, Möller H, Zohar J, Hollander E, Kasper S, Möller H, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin D, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein D, Lader M, Lecrubier Y, Lépine J, Liebowitz M, Lopez-Ibor J, Marazziti D, Miguel E, Oh K, Preter M, Rupprecht R, Sato M, Starcevic V, Stein D, van Ameringen M, Vega J. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. The World Journal Of Biological Psychiatry 2008, 9: 248-312. PMID: 18949648, DOI: 10.1080/15622970802465807.Peer-Reviewed Original ResearchConceptsSerotonin-noradrenaline reuptake inhibitorsPost-traumatic stress disorderSelective serotonin reuptake inhibitorsObsessive-compulsive disorderPharmacological treatmentCognitive behavioral therapyReuptake inhibitorsStress disorderTricyclic antidepressantsSSRI/SNRIAnxiety disordersBiological Psychiatry (WFSBP) GuidelinesFirst-line treatmentRelapse prevention studySerotonin reuptake inhibitorsTreatment-resistant casesPotential treatment optionSubstance abuse disordersWorld FederationObsessive-CompulsiveStudy of anxiolyticsOpen studySustained efficacyStandard treatmentTreatment options
2005
Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder
Fontenelle L, Mendlowicz M, Miguel E, Versiani M. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder. The World Journal Of Biological Psychiatry 2005, 6: 57-59. PMID: 16097406, DOI: 10.1080/15622970510029740.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderSRI-resistant obsessive compulsive disorderResistant obsessive-compulsive disorderCombination of citalopramFirst-line treatmentAdequate trialReuptake inhibitorsCompulsive disorderPatientsCitalopramDisordersFuture studiesTrials